CD8A and neoplasm: Furthermore, NanoMnSor reprogrammed tumor-promoting macrophages toward immunostimulatory M1 macrophages, increased CD8+ cytotoxic T cells in tumors, and amplified the efficacy of the PD-L1 antibody (Fig. 8).